Evidence map›Paper›PMID 34159077›Full record

ArticleTranslational andrology and urology2021

Intermediate-term results of a prospective, multicenter study on remote programming sacral neuromodulation for refractory overactive bladder.

Yaoguang Zhang, Lingfeng Meng, Peng Zhang, Xiaojun Tian, Guoqing Chen, Yan Li, Yong Zhang, Zhihui Xu, Zhongqing Wei, Wei Zhang and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational andrology and urology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Yaoguang ZhangUrology Department, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences Beijing, China.
Lingfeng MengUrology Department, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences Beijing, China.
Peng ZhangUrology Department, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.
Xiaojun TianUrology Department, Peking University Third Hospital, Beijing, China.
Guoqing ChenUrology Department, China Rehabilitation Research Center, Beijing, China.
Yan LiUrology Department, Qilu Hospital, Shandong University, Jinan, China.
Yong ZhangUrology Department, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Zhihui XuUrology Department, Zhejiang Provincial People's Hospital, Hangzhou, China.
Zhongqing WeiUrology Department, Second Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Wei ZhangPeking University Fifth School of Clinical Medicine, Beijing, China.
Lulin MaUrology Department, Peking University Third Hospital, Beijing, China.
Benkang ShiUrology Department, Qilu Hospital, Shandong University, Jinan, China.
Limin LiaoUrology Department, China Rehabilitation Research Center, Beijing, China.
Jianye WangUrology Department, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTo evaluate the efficacy and safety of a novel remote programming sacral neuromodulation (SNM) system (BetterStim system) in the treatment of patients with refractory overactive bladder (OAB) for 3 years.

methodsA total of 8 centers in China enrolled 84 patients with OAB. Following test stimulation 70 patients underwent implantation using BetterStim. All patients returned for follow-up at 3 and 6 months postoperatively. After that, the visits were conducted by telephone. Outcomes of voiding diaries, the overactive bladder symptom score (OABSS), questionnaires regarding OAB-related quality of life (OAB-qol), and adverse events (AEs) were evaluated at each visit. The clinical therapeutic success was defined as ≥50% improvement from baseline in any of the voiding diary variables or average voids/day return to normal voiding (<8 voids/day). The analysis is a modified Completers analysis.

resultsAt the 36-month follow-up, the success rate was 79% for overall OAB symptoms, 69% for urge urinary incontinence (UUI) and 42% for urgency frequency (UF). The average number of voids/day decreased from 29.2±14.9 at baseline to 17.6±11.2 at 3 years, the average volume/void increased from 94.7±54.2 to 151.4±80.8 mL, the urgency reduced from 3.0±1.4 to 1.8±1.7 (all P<0.001). For patients with urge incontinence, mean leaking episodes/day decreased from 8.1±7.6 at baseline to 2.1±3.5 at three years (P<0.05). The devices were explanted in 8 (11.4%) patients. There were no remote programming-related AEs or device-related serious AEs that occurred.

conclusionsThe Intermediate-term results demonstrated that BetterStim SNM system with remote programming is safe and effective for patients with refractory OAB.

Indexed as

overactive bladder (OAB)remote programmingSacral neuromodulation (SNM)

Identifiers

PMID34159077
PMCPMC8185673

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.